<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">51102</article-id><article-id pub-id-type="doi">10.7554/eLife.51102</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>A novel role for lipoxin A4 in driving a lymph node-eye axis that controls autoimmunity to the neuroretina</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-143406"><name><surname>Wei</surname><given-names>Jessica</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7329-2812</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-154118"><name><surname>Mattapallil</surname><given-names>Mary J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-154117"><name><surname>Horai</surname><given-names>Reiko</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-154119"><name><surname>Jittayasothorn</surname><given-names>Yingyos</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-154120"><name><surname>Modi</surname><given-names>Arnav P</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-154121"><name><surname>Sen</surname><given-names>H Nida</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-147466"><name><surname>Gronert</surname><given-names>Karsten</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5329-7907</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-49383"><name><surname>Caspi</surname><given-names>Rachel R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Vision Science Program, School of Optometry</institution>, <institution>University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">NEI</institution>, <institution>NIH</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">School of Optometry</institution>, <institution>University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Lab. Immunol., NEI</institution>, <institution>NIH</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-17809"><name><surname>Smith</surname><given-names>Lois</given-names></name><role>Reviewing editor</role><aff><institution>Boston Children's Hospital/Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>kgronert@berkeley.edu</email> (KG);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>caspir@nei.nih.gov</email> (RC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>03</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e51102</elocation-id><history><date date-type="received"><day>15</day><month>08</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>02</month><year>2020</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-51102-v1.pdf"/><abstract><p>The eicosanoid lipoxin A<sub>4 </sub>(LXA<sub>4</sub>) has emerging roles in lymphocyte-driven diseases. We identified reduced LXA<sub>4</sub> levels in posterior segment uveitis patients and investigated the role of LXA<sub>4</sub> in the pathogenesis of experimental autoimmune uveitis (EAU). Immunization for EAU with a retinal self-antigen caused selective downregulation of LXA<sub>4</sub> in lymph nodes draining the site of immunization, while at the same time amplifying LXA<sub>4</sub> in the inflamed target tissue. T cell effector function, migration and glycolytic responses were amplified in LXA<sub>4</sub>-deficient mice, which correlated with more severe pathology, whereas LXA<sub>4</sub> treatment attenuated disease. <italic>In vivo</italic> deletion or supplementation of LXA<sub>4</sub> identified modulation of CC-chemokine receptor 7 (CCR7) and sphingosine 1- phosphate receptor-1 (S1PR1) expression and glucose metabolism in CD4<sup>+</sup> T cells as potential mechanisms for LXA<sub>4</sub> regulation of T cell effector function and trafficking. Our results demonstrate the intrinsic lymph node LXA<sub>4</sub> pathway as a significant checkpoint in the development and severity of adaptive immunity.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>EY026082</award-id><principal-award-recipient><name><surname>Gronert</surname><given-names>Karsten</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000053</institution-id><institution>National Eye Institute</institution></institution-wrap></funding-source><award-id>EY000184</award-id><principal-award-recipient><name><surname>Caspi</surname><given-names>Rachel R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experimental procedures were approved by the Animal Care and Use program at University of California, Berkeley, and the National Eye Institute at the National Institutes of Health.(protocol AUP-2016-04-8691-1),</p></fn><fn fn-type="other"><p>Human subjects: Male and female patients ages 30 - 76 with clinical diagnosis of non-infectious posterior segment uveitis were enrolled in the National Eye Institute protocol number 16-EI-0046. Healthy controls were NIH blood bank donors of both sexes with a similar age range. Serum samples were obtained from male and female patients ages 30 - 76 with clinical diagnosis of non-infectious posterior uveitis, healthy controls were NIH blood bank donors of both sexes with a similar age range whose samples were de-identified and sent to the lab. Patients were enrolled from May 2017 to July 2018 under a clinical research protocol 428 (NCT02656381), approved by the institutional review board of the National Institutes of Health. Informed consent (including publishing language as required by NIH IRB) were obtained from all subjects. The study adhered to the tenets of the Declaration of Helsinki.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data needed to evaluate the conclusions of the paper are present in the main text and Supplementary Materials.</p></sec><supplementary-material><ext-link xlink:href="elife-51102-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>